News Sentiment

EXEL sentiment intelligence

Exelixis Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 70 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 51.91 Week of 19 Jun 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 63

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-2.3% over one week, +3.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

Market Reaction

Balanced read

66/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction -2.3% Price reacting lower
Trend fit Trend active 3.5% over four weeks
Fair value 59.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 27
Neutral 36
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 63
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
simplywall.st 6
MarketBeat 6
Stock Titan 6
AD HOC NEWS 4
TradingKey 4
Business Wire 3
Investing.com 3

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 31
Regulatory and legal 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 70
MarketBeat Direct company coverage

Exelixis, Inc. $EXEL Shares Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets significantly increased its stake in Exelixis, Inc. (NASDAQ:EXEL) by 79.5% during the fourth quarter, bringing its total holdings to over 1.1 million shares valued at approximately $49 million. This increase follows Exelixis reporting better-than-exp

Tone
Positive 72/100
Event
Earnings
Published
01 Jun 2026 17:09
Source
MarketBeat
Investing.com Direct company coverage

Exelixis presents Cabometyx data for neuroendocrine tumors

Exelixis (NASDAQ:EXEL) presented positive subgroup analysis data from its phase 3 CABINET trial for Cabometyx in neuroendocrine tumors at the American Society of Clinical Oncology Annual Meeting. The results showed a significant reduction in the risk of disease progression or dea

Tone
Positive 74/100
Event
Earnings
Published
31 May 2026 11:10
Source
Investing.com
Investing.com Australia Direct company coverage

Exelixis presents Cabometyx data for neuroendocrine tumors By Investing.com

Exelixis (NASDAQ:EXEL) has released positive subgroup analysis results from its Phase 3 CABINET trial for Cabometyx in advanced neuroendocrine tumors. The study showed significant reduction in disease progression or death risk in both functional and non-functional tumor patients.

Tone
Positive 82/100
Event
Earnings
Published
30 May 2026 14:40
Source
Investing.com Australia
marketscreener.com Direct company coverage

Exelixis says Cabometyx reduces risk of progression or death by 74% in non-functional net, 60% in functional net

Exelixis announced that its drug Cabometyx significantly reduced the risk of disease progression or death in patients with non-functional and functional neuroendocrine tumors (NETs). Specifically, Cabometyx demonstrated a 74% reduction in risk for those with non-functional NETs a

Tone
Positive 74/100
Event
Market update
Published
30 May 2026 13:40
Source
marketscreener.com